Werner Jaross
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Werner Jaross has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Mario Menschikowski
Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty, Technical University of Dresden, Germany
1 shared publicationRolf Eckey
Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty, Technical University of Dresden, Germany
1 shared publication
Latest Publications
- 13 June 2002
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 32 (6) , 383-393
Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis
Secretory phospholipase A2 group IIA(sPLA2 IIA) can be produced and secreted by various cell types either constitutionally or as an acute‐phase reactant upon stimulation by proinflammatory cytokines. The enzyme prefers phosphatidylethanolamine and phosphatidylserine as substrates. One important biological function may be the hydrolytic destruction of bacterial membranes. It has been demonstrated, however, that sPLA2 can also hydrolyse the phospholipid monolayers of high density lipoprotein (HDL) and low density lipoprotein (LDL) in vitro. Secretory phospholipase A2‐modified LDL show increased affinity to glycosaminoglycans and proteoglycans, a tendency to aggregate, and an enhanced ability to deliver cholesterol to cells. Incubation of cultured macrophages with PLA2‐treated LDL and HDL is associated with increased intracellular lipid accumulation, resulting in the formation of foam cells. Elevated sPLA2(IIA) activity in blood serum leads to an increased clearance of serum cholesterol. Secretory phospholipase A2(IIA) can also be detected in the intima, adventitia and media of the atherosclerotic wall not only in developed lesions but also in very early stages of atherosclerosis. The presence of DNA of Chlamydia pneumoniae, herpes simplex virus, and cytomegalovirus was found to be associated with sPLA2(IIA) expression and other signs of local inflammation. Thus, sPLA2(IIA) appears to be one important link between the lipid and the inflammation hypothesis of atherosclerosis.
- 13 June 2002
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 32 (6) , 383-393
Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis
Secretory phospholipase A2 group IIA(sPLA2 IIA) can be produced and secreted by various cell types either constitutionally or as an acute‐phase reactant upon stimulation by proinflammatory cytokines. The enzyme prefers phosphatidylethanolamine and phosphatidylserine as substrates. One important biological function may be the hydrolytic destruction of bacterial membranes. It has been demonstrated, however, that sPLA2 can also hydrolyse the phospholipid monolayers of high density lipoprotein (HDL) and low density lipoprotein (LDL) in vitro. Secretory phospholipase A2‐modified LDL show increased affinity to glycosaminoglycans and proteoglycans, a tendency to aggregate, and an enhanced ability to deliver cholesterol to cells. Incubation of cultured macrophages with PLA2‐treated LDL and HDL is associated with increased intracellular lipid accumulation, resulting in the formation of foam cells. Elevated sPLA2(IIA) activity in blood serum leads to an increased clearance of serum cholesterol. Secretory phospholipase A2(IIA) can also be detected in the intima, adventitia and media of the atherosclerotic wall not only in developed lesions but also in very early stages of atherosclerosis. The presence of DNA of Chlamydia pneumoniae, herpes simplex virus, and cytomegalovirus was found to be associated with sPLA2(IIA) expression and other signs of local inflammation. Thus, sPLA2(IIA) appears to be one important link between the lipid and the inflammation hypothesis of atherosclerosis.